Adaptive resistance: A tumor strategy to evade immune attack

Sheng Yao, Lieping Chen

Research output: Contribution to journalArticle

Abstract

A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.

Original languageEnglish (US)
Pages (from-to)576-579
Number of pages4
JournalEuropean Journal of Immunology
Volume43
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Allergy and Immunology
Inducible T-Cell Co-Stimulator Ligand
Neoplasms
Active Immunity
T-Lymphocytes
T-Cell Leukemia
Immune Tolerance
Myeloid Cells
Acute Myeloid Leukemia
Immunotherapy
Immune System
Up-Regulation
Down-Regulation
Ligands
Phenotype
Pressure
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Adaptive resistance : A tumor strategy to evade immune attack. / Yao, Sheng; Chen, Lieping.

In: European Journal of Immunology, Vol. 43, No. 3, 03.2013, p. 576-579.

Research output: Contribution to journalArticle

Yao, Sheng ; Chen, Lieping. / Adaptive resistance : A tumor strategy to evade immune attack. In: European Journal of Immunology. 2013 ; Vol. 43, No. 3. pp. 576-579.
@article{39a6195176bd46298cfc7a2208834297,
title = "Adaptive resistance: A tumor strategy to evade immune attack",
abstract = "A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.",
author = "Sheng Yao and Lieping Chen",
year = "2013",
month = "3",
doi = "10.1002/eji.201243275",
language = "English (US)",
volume = "43",
pages = "576--579",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Adaptive resistance

T2 - A tumor strategy to evade immune attack

AU - Yao, Sheng

AU - Chen, Lieping

PY - 2013/3

Y1 - 2013/3

N2 - A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.

AB - A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.

UR - http://www.scopus.com/inward/record.url?scp=84874968769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874968769&partnerID=8YFLogxK

U2 - 10.1002/eji.201243275

DO - 10.1002/eji.201243275

M3 - Article

C2 - 23381914

AN - SCOPUS:84874968769

VL - 43

SP - 576

EP - 579

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 3

ER -